Page 1230 - Adams and Stashak's Lameness in Horses, 7th Edition

1196 Index

nonsteroidal anti‐inflammatory drugs prepurchase examination (PPE), 1174 osteoarthritis (OA)
(NSAIDs), 900–903 principles, 342–343 carpus, 615–616
acetylsalicylic acid, 901–902
carpometacarpal osteoarthritis, 616, 617
VetBooks.ir carprofen, 903 sacroiliac region diseases, 781–782 clinical signs, 615, 616
radiation safety and protection, 343
As Low As Reasonably Achievable
diagnosis, 615, 616
commonly used NSAIDs, 900–901
(ALARA), 343
etiology, 615
facet joint arthritis and vertebral facet joint
syndrome, 791–792
treatment, 615–616
firocoxib, 902–903 scintigraphic signs of disease, 356–360 prognosis, 615–616
blood flow or vascular phase,
flunixin meglumine, 901 356–357 cervical facet joints, 797–798
laminitis, 499–501 delayed or bone phase, 358–361 coxofemoral (hip) joint, 757–758
meclofenamic acid (MA), 902 pool or soft tissue phase, 357–358 clinical signs, 757
medication effects on bone, 846 spine, 346 diagnosis, 757, 758
meloxicam, 903 tarsus, diagnosis of tarsal lameness, 660 etiology, 757
naproxen, 902 thoracic limb, 346 prognosis, 758
navicular syndrome/disease, 451 nutraceuticals, 903–907 treatment, 757–758
parenteral NSAIDs, 875 avocado and soybean unsaponifiable distal interphalangeal (DIP) joint, 463–465
phenylbutazone, 901 extracts, 906 clinical signs, 463–464
topical NSAIDs, 881 chondroitin sulfate (CS), 905 diagnosis, 464
vedaprofen, 903 collagen hydrolysate (CH), 906–907 etiology, 463
nuchal ligament fatty acids, 906 prognosis, 465
neck and poll, 796–797 glucosamine (GLN), 904–905 treatment, 464–465
clinical signs, 796 glucosamine and chondroitin sulfate, 905 distal tarsal (DT) joints/DT joint pain,
diagnosis, 796–797 hyaluronan (or hyaluronic acid, HA), 662–672
etiology, 796 905–906 advanced treatment procedures,
prognosis, 797 methylsulfonylmethane (MSM), 906 669–672
treatment, 797 resveratrol, 907 bisphosphonates, 668
nuclear medicine, 342–373 vitamins, minerals, trace elements, and chemical‐induced arthrodesis: ethyl
bone, abnormal conditions, 360–372 herbs, 907 alcohol, 670–672
carpus, 364, 365 nutritional secondary hyperparathyroidism diagnosis, 663–664
coxofemoral (hip) joint, 368, 371, 371 (osteodystrophia fibrosa), 844–845 diagnostic analgesia, 664–665
distal limb (foot, pastern, and fetlock), differentiating DT joint pain from
361, 363, 362–363 OA see osteoarthritis proximal plantar region pain, 666–667
elbow joint, 366 objective assessment of lameness, 139–155 etiology, 662–663
metacarpus, 363–364, 364, 365 see also under kinematics extracorporeal shockwave therapy
metatarsus, 363–364, 364, 365 kinematics (measurement of movement), (ESWT), 668
pelvis, 368, 371, 370 140–155 farriery, 668–669
proximal limb long bones, 364, 366, kinetics (measurement of ground reaction imaging, 665–666
365, 367 forces), 139–140 intra‐articular medications, 667–668
sacroiliac (SI) joint, 368, 371, 371 OC see osteochondrosis laser arthrodesis, 670
scapula, 366, 368 occupational‐related lameness conditions, magnetic resonance imaging (MRI), 666
shoulder joint, 366, 368 69, 70 nuclear medicine, 666
spine, 371–372, 371–373 see also draft horses; endurance horses; radiography, 665
stifle joint, 368, 370 gaited horses; jumping/eventing/ surgical arthrodesis of DIT and TMT
tarsus, 366–367, 364, 365 dressage; racing Quarter horses; joints, 669–670
bone, normal, 348–356 Standard bred racehorses; treatment, 667–672
carpus, 351 thoroughbred racehorses; western draft horses
coxofemoral (hip) joint, 353–355, 355 performance horses; western pleasure distal interphalangeal (DIP) joint, 1029
distal limb (foot, pastern, and fetlock), horses lower hock joint OA, 1029
350, 349–351 OCD see osteochondritis dissecans proximal interphalangeal (PIP) joint
elbow joint, 351, 353 olecranon bursitis (bursitis of the elbow), (high ringbone), 1029
metacarpus, 351, 351 632–633 fetlock osteoarthritis, western pleasure
metatarsus, 351, 351 clinical signs, 633 horses, 1010
pelvis, 353–355 diagnosis, 633 intervertebral thoracolumbar facet OA,
sacroiliac (SI) joint, 353–355 etiology, 633 jumping/eventing/dressage, 995
scapula, 353 prognosis, 633 metacarpophalangeal/metatarsophalangeal
shoulder joint, 351, 353 treatment, 633 joint, 550–552
spine, 355–356 osseous and osteochondral pathology, carpal clinical signs, 550
stifle joint, 351, 353 region, magnetic resonance imaging diagnosis, 551
tarsus, 351 (MRI), 421 etiology, 550
upper limb long bones, 351 osseous cyst‐like lesions, tarsal region, prognosis, 552
distal tarsal (DT) joints/DT joint pain, magnetic resonance imaging treatment, 552
osteoarthritis (OA), 666 (MRI), 423 pathways to morphologic breakdown of
foot, 346–347 osseous injury of the third metacarpal/ articular cartilage: the critical
imaging equipment, 343–344 metatarsal bone, metacarpal/ manifestation of OA, 813–814
gamma camera, 343–344 metatarsal regions, magnetic physiologic trauma leading to
limitations, 373 resonance imaging (MRI), osteoarthritis, 809
musculoskeletal system 419–420 proximal interphalangeal (PIP) joint (high
indications for nuclear medicine, osseous trauma ringbone)
347–348 tarsal region, magnetic resonance imaging clinical signs, 513–514
method for a scintigraphic exam, (MRI), 422, 423 conservative management, 515–516
344–347 osseous trauma of the proximal phalanx, diagnosis, 514–515
pelvic limb, 346 magnetic resonance imaging (MRI), etiology, 512–513
phases, 342–343 411–412 prognosis, 517
blood flow or vascular phase, 342, 347, ossification of the collateral cartilages surgical treatment, 516–517
356–357 distal phalanx (sidebone), 474–475 treatment, 515–517
delayed or bone phase, 342, 348, clinical signs, 474–475 scapulohumeral (SH) joint or shoulder,
358–360 diagnosis, 475 646–648
pool or soft tissue phase, 342, 347–348, etiology, 474 clinical signs, 647
357–358 treatment, 475 diagnosis, 647